INS and diabetes mellitus: Insulin biosimilar showed comparable characteristics with the reference drug in terms of efficacy, safety, and immunogenicity through comprehensive and specific conventional meta-analysis, even in the subgroup analysis of the different types of diabetes and different duration of insulin.